- Ticker
- ABVC
- Price
- 0.72
- Stock movement up
- +0.02 (2.40%)
- Company name
- ABVC Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 23.50M
- Ent værdi
- 26.96M
- Pris/omsætning
- 68.50
- Pris/bog
- 4.13
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- -70.97%
- 3 års afkast
- -52.57%
- 5 års afkast
- -87.58%
- 10 års afkast
- -
Senest opdateret: 2023-02-06
UDBYTTE
ABVC betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 68.50 |
| Pris til egenkapital | 4.13 |
| EV i forhold til salg | 78.60 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 32.63M |
| EPS (TTM) | -0.60 |
| FCF pr. aktie (TTM) | -0.28 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 343.00K |
| Bruttofortjeneste (TTM) | 319.19K |
| Driftsindkomst (TTM) | -18.43M |
| Nettoindkomst (TTM) | -19.49M |
| EPS (TTM) | -0.60 |
| EPS (1 år frem) | -0.36 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 93.06% |
| Driftsmargin (TTM) | -5372.83% |
| Fortjenstmargin (TTM) | -5682.74% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 1.32M |
| Nettotilgodehavender | 547.68K |
| Omsætningsaktiver i alt | 2.90M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 10.48M |
| Kreditor | 0.00 |
| Kortfristet/nuværende langsigtet gæld | 3.11M |
| Summen af kortfristede forpligtelser | 3.89M |
| Sum gæld | 4.79M |
| Aktionærernes egenkapital | 5.69M |
| Materielle nettoaktiver | 5.92M |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -8.99M |
| Investeringsudgifter (TTM) | 212.82K |
| Fri pengestrøm (TTM) | -9.02M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -342.37% |
| Afkast af aktiver | -185.98% |
| Afkast af investeret kapital | -246.01% |
| Kontant afkast af investeret kapital | -113.84% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.71 |
| Daglig høj | 0.73 |
| Daglig lav | 0.71 |
| Daglig volumen | 27K |
| Højeste gennem alle tider | 716331.21 |
| 1 års analytiker estimat | 9.50 |
| Beta | 0.28 |
| EPS (TTM) | -0.60 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 29 Mar 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ABVC | S&P500 | |
| Nuværende prisfald fra top notering | -100.00% | -14.21% |
| Højeste prisfald | -100.00% | -56.47% |
| Højeste efterår dato | 6 Feb 2023 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -91.23% | -11.49% |
| Gennemsnitlig tid til nyt højdepunkt | 119 days | 13 days |
| Maks. tid til nyt højdepunkt | 1729 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
23.50M
Markedsværdi kategori
Small-cap
Beskrivelse
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Personale
28
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
19. januar 2023
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Several potential paths to near-term milestones… ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies fo...
18. januar 2023
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
5. januar 2023
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Adding venues and enrolling patients to advance assets … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing ther...
20. december 2022
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
17. november 2022
ABVC BioPharma ( NASDAQ:ABVC ) Third Quarter 2022 Results Key Financial Results Net loss: US$3.70m (loss widened by...
17. november 2022
FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
14. november 2022
FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
7. november 2022
FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
2. november 2022
FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
5. oktober 2022
Næste side